RANS. Study in Patients with Severe Eosinophilic Asthma and Nasal Polyps. - RANS

Study identifier:D3250R00099

ClinicalTrials.gov identifier:NCT05180357

EudraCT identifier:N/A

CTIS identifier:N/A

Study Complete

Official Title

Retrospective, Observational Study in Patients with Severe Eosinophilic Asthma and Nasal Polyps treated by FASENRA®

Medical condition

Severe Eosinophilic Asthma

Phase

N/A

Healthy volunteers

No

Study drug

-

Sex

All

Actual Enrollment

252

Study type

Observational

Age

N/A

Date

Study Start Date: 23 Nov 2021
Primary Completion Date: 28 Oct 2022
Study Completion Date: 28 Oct 2022

Study design

Allocation: N/A
Endpoint Classification: -
Intervention Model: -
Masking: -
Primary Purpose: -

Verification:

Verified 01 Nov 2022 by AstraZeneca

Sponsors

AstraZeneca

Collaborators

-

Inclusion and exclusion criteria